Welcome to our dedicated page for Bionano Genomics SEC filings (Ticker: BNGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bionano Genomics, Inc. filings document the formal disclosures of a genome-analysis company commercializing optical genome mapping solutions, diagnostic testing services, genome-analysis software and nucleic acid extraction and purification technologies. Form 8-K reports record financial results, preliminary results, material agreements, securities offerings and executive leadership changes, while registration statements describe offered common stock, pre-funded warrants and warrant securities.
Proxy materials cover board elections, executive compensation, equity-award matters, shareholder voting and governance practices. The filing record also documents capital-structure changes, Nasdaq-listed common stock disclosures, risk factors and exhibits tied to Bionano’s OGM, VIA software, Ionic system and Bionano Laboratories operations.
Bionano Genomics has fully repaid its Senior Secured Convertible Debentures, removing all secured debt from its balance sheet. The company used cash on hand to retire and cancel debentures with an aggregate face value of $20,000,000, originally issued in May 2024 and repaid at their scheduled maturity on May 26, 2026.
All liens on Bionano’s assets and the associated restrictive covenants have been terminated, which the company says provides meaningfully greater financial and operational flexibility. Management describes the debt retirement as a significant milestone that simplifies the financial profile and allows more focus on growing adoption of its optical genome mapping solutions and executing its commercial strategy.
Bionano Genomics director Aleksandar Rajkovic received a grant of stock options for 9,149 shares of common stock at an exercise price of $1.19 per share. These options vest in equal monthly installments over 12 months and expire on May 13, 2036.
The award is standard equity compensation, not an open‑market stock purchase or sale. The options will be fully vested by the company’s next annual stockholder meeting or upon a qualifying Change of Control, assuming continuous service through each vesting date.
Bionano Genomics, Inc. director Yvonne Linney received a grant of stock options covering 9,149 shares of common stock. The options have an exercise price of $1.19 per share and expire on May 13, 2036.
The award vests in equal monthly installments over 12 months, and will be fully vested by the company’s next annual stockholder meeting, subject to her continuous service. The options also vest in full upon a Change of Control as defined in the company’s 2018 equity incentive plan.
Bionano Genomics director Kristiina Vuori, MD received a new stock option grant. She was awarded options covering 9,149 shares of common stock at an exercise price of $1.19 per share. These options are held directly and represent compensation rather than an open-market purchase.
The options will vest in equal monthly installments over 12 months following the grant date and will in any case be fully vested by the company’s next annual stockholder meeting, so long as her continuous service continues through each vesting date. The award also fully vests upon a Change of Control under the company’s 2018 equity incentive plan, and expires on May 13, 2036 if not exercised.
Bionano Genomics director Christopher J. Twomey received a grant of stock options covering 9,149 shares of common stock at an exercise price of $1.19 per share. These options vest in equal monthly installments over 12 months and will be fully vested by the next annual stockholder meeting or upon a qualifying change of control. Following this grant, he holds options on 9,149 shares that expire on May 13, 2036.
Bionano Genomics director David L. Barker received a new stock option grant as part of his compensation. The award covers 9,149 shares of common stock at an exercise price of $1.19 per share, with no cash paid at grant.
The option vests in equal monthly installments over the 12 months following the grant date and will in any case be fully vested by the date of the company's next annual stockholder meeting, as long as Barker maintains continuous service. The award will also vest in full upon a qualifying Change of Control under the company's 2018 equity incentive plan.
Bionano Genomics, Inc. held its 2026 Annual Meeting of Stockholders and reported voting results on three proposals. As of the March 19, 2026 record date, 11,091,615 common shares were outstanding and entitled to vote, with 4,225,995 shares represented, or about 38.1% participation.
Stockholders elected Class II directors Albert Luderer, Ph.D. and Kristiina Vuori, M.D., Ph.D., each to serve until the 2029 annual meeting or earlier departure. They also approved, on an advisory basis, compensation of named executive officers and ratified BDO USA, P.C. as independent auditor for the fiscal year ending December 31, 2026.
Bionano Genomics, Inc. reported Q1 2026 revenue of $6.7M, up 4% year over year, driven by higher instrument, consumable, and service revenue, partly offset by lower software sales. Product revenue was $6.1M and service and other revenue $0.6M.
The company’s net loss widened to $8.3M from $3.1M, with operating cash outflows of $5.7M. As of March 31, 2026, Bionano held $3.4M in cash and cash equivalents, $11.0M in short-term investments, and $10.3M in restricted cash and investments.
Management states there is substantial doubt about the company’s ability to continue as a going concern within 12 months without significant new capital. Bionano has $10.3M of Senior Secured Convertible Debentures outstanding and is relying on additional equity or debt financing to fund operations beyond the near term.
Bionano Genomics reported Q1 2026 revenue of $6.7 million, up 4% from $6.5 million a year earlier, with improving margins but a wider loss. Gross margin reached 49%, compared to 46% in Q1 2025, supported by higher consumables use and services.
Consumables revenue was $3.9 million, up 20%, and the company sold 8,178 nanochannel array flow cells, a 17% increase. Operating expenses declined 2% to $11.1 million, but net loss widened to $8.3 million from $3.1 million, partly reflecting weaker other income.
Bionano highlighted reimbursement tailwinds, including a new Category I CPT code 81354 effective January 1, 2026 and a 47% payment increase for CPT code 81195 to $1,853.22. The company guided Q2 2026 revenue to $7.5–$7.8 million and full-year 2026 revenue to $30–$33 million, and reiterated expectations to retire its secured convertible debt.
Bionano Genomics, Inc. filed a shelf registration statement to offer and sell up to $400,000,000 of common stock, preferred stock, debt securities, warrants and/or units. The prospectus is a general shelf: specific terms, prices and amounts for any offering will be provided in prospectus supplements.
The filing replaces a prior registration and permits issuance of securities covered by the earlier statement until the earlier of effectiveness or November 6, 2026. Net proceeds are intended for general corporate purposes, including working capital, R&D, repayment of indebtedness and capital expenditures.